Lin M, Wang CL, Chen FS, Ho LH. Fatal hemolytic transfusion reaction due to anti-Ku in a K null patient. Immunohematology 2003;19:19–21.10.21307/immunohematology-2019-469
Manoura A, Korakaki E, Hatzidaki E, et al. Use of recombinant erythropoietin for the management of severe hemolytic disease of the newborn of a K0phenotype mother. Pediatr Hematol Oncol 2007;24:69–73.10.1080/0888001060100145317130116
Lydaki E, Nikoloudi I, Kaminopetros P, et al. Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku. Transfusion 2005;45:1791–5.10.1111/j.1537-2995.2005.00604.x16271105
Corcoran PA, Allen FH Jr, Lewis M, Chown B. A new antibody, anti-Ku (anti-Peltz), in the Kell blood-group system. Transfusion 1961;1:181–3.10.1111/j.1537-2995.1961.tb00036.x13695467
Subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297–316.10.1542/peds.114.1.29715231951
Lee S, Russo DC, Reid ME, Redman CM. Mutations that diminish expression of Kell surface protein and lead to the KmodRBC phenotype. Transfusion 2003;43:1121–5.10.1046/j.1537-2995.2003.00472.x12869119